Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Aug 1;35(8):1412-1419.
doi: 10.1093/ndt/gfz116.

New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review

Cheng Xue  1 , Yan-Yan Gu  2 , Cheng-Ji Cui  3 , Chen-Chen Zhou  4 , Xian-Dong Wang  5 , Meng-Na Ruan  1 , Lin-Xi Huang  1 , Si-Xiu Chen  1 , Bo Yang  1 , Xu-Jiao Chen  1 , Yi-Xin Qian  1 , Jun Wu  1 , Xue-Zhi Zhao  1 , Yu-Qiang Zhang  1 , Chang-Lin Mei  1 , Shou-Lin Zhang  3 , Jing Xu  1 , Zhi-Guo Mao  1
Affiliations
Meta-Analysis

New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review

Cheng Xue et al. Nephrol Dial Transplant. .

Abstract

Background: Peritoneal dialysis (PD) patients are at high risk of developing glucose metabolism disturbance (GMD). The incidence and prevalence of new-onset GMD, including diabetes mellitus (DM), impaired glucose tolerance (IGT) and impaired fast glucose (IFG), after initiation of PD, as well as their correlated influence factors, varies among studies in different areas and of different sample sizes. Also, the difference compared with hemodialysis (HD) remained unclear. Thus we designed this meta-analysis and systematic review to provide a full landscape of the occurrence of glucose disorders in PD patients.

Methods: We searched the MEDLINE, Embase, Web of Science and Cochrane Library databases for relevant studies through September 2018. Meta-analysis was performed on outcomes using random effects models with subgroup analysis and sensitivity analysis.

Results: We identified 1124 records and included 9 studies involving 13 879 PD patients. The pooled incidence of new-onset DM (NODM) was 8% [95% confidence interval (CI) 4-12; I2 = 98%] adjusted by sample sizes in PD patients. Pooled incidence rates of new-onset IGT and IFG were 15% (95% CI 3-31; I2 = 97%) and 32% (95% CI 27-37), respectively. There was no significant difference in NODM risk between PD and HD [risk ratio 0.99 (95% CI 0.69-1.40); P = 0.94; I2 = 92%]. PD patients with NODM were associated with an increased risk of mortality [hazard ratio 1.06 (95% CI 1.01-1.44); P < 0.001; I2 = 92.5%] compared with non-DM PD patients.

Conclusions: Around half of PD patients may develop a glucose disorder, which can affect the prognosis by significantly increasing mortality. The incidence did not differ among different ethnicities or between PD and HD. The risk factor analysis did not draw a definitive conclusion. The glucose tolerance test should be routinely performed in PD patients.

Keywords: de novo; diabetes mellitus; glucose metabolism disturbance; hemodialysis; peritoneal dialysis.

PubMed Disclaimer

Publication types